SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger

SeQuent Scientific Ltd. ("SeQuent"), a leading player in the global Animal Health industry, and Viyash Lifesciences Private Limited ("Viyash"), an integrated global pharmaceutical company, announced today that the National Company Law Tribunal (NCLT) has allowed the petition and approved the Scheme of merger between SeQuent and the Viyash group of companies. The NCLT approval marks the beginning of a new chapter for the combined entity, and represents a fundamental transformation to leapfrog into the next orbit of the global animal health market. The combined financial performance of the companies with aggregate H1FY26 revenues of INR 16.5bn and aggregate H1FY26 EBITDA of INR 3.2bn, with a Net Debt to EBITDA ratio of 0.7x, represents significant scale as the largest animal health player from India.

As highlighted earlier, the combined entity is aligned to capitalise on two major long-term industry opportunities:

1. Global, fast-growing Companion (Pet) Animal Health segment - The inherent growth in the market provides a large opportunity, driven by increased pet adoption and emerging treatments for Bone & Joint disease, Dermatitis, Diabetes, Cardiology and Oncology, similar to human pharmaceutical applications.

2. Genericization of Animal Health, which lags significantly behind Human Health - This provides a substantial opportunity for the combined company to leverage its technical strengths in APIs and Formulations. In addition, the advanced capabilities in R&D would help strengthen its fastgrowing CDMO business.

This merger not only delivers the necessary scale and capabilities for accelerating organic growth in the Animal Health market, but also provides financial resilience, stability, and management bandwidth to rejuvenate SeQuent's inorganic growth engine.

Dr. Haribabu Bodepudi, Founder and CEO, Viyash, said, "This merger creates the platform to deliver world-class solutions for our customers. With our strengths in R&D, custom development capabilities, manufacturing capacities, and a streamlined supply chain, we would emerge as an innovative and reliable partner for our customers across the world. Over the last few months, we have developed a comprehensive plan for integration which leverages synergies for growth and capability. The momentum reflected in our recent results is only the beginning."

Commenting on the merger, Mr. Rajaram Narayanan, Managing Director and CEO of SeQuent, said, "We are pleased to receive the approval from the Hon'ble NCLT, marking the start of a transformative journey for the combined entity. There are significant opportunities to provide relevant, differentiated and quality care for animals. With this merger, the Company will be uniquely positioned to build a world-class business and deliver on the requirements of pet owners, farmers and animal health professionals. Together, we are building a company that will set new benchmarks in quality, innovation, and customer trust."

Shares of Sequent Scientific Limited was last trading in BSE at Rs. 247.65 as compared to the previous close of Rs. 231.35. The total number of shares traded during the day was 507670 in over 8363 trades.

The stock hit an intraday high of Rs. 249.50 and intraday low of 229.80. The net turnover during the day was Rs. 123628417.00.

Source : Equity Bulls

Keywords

SequentScientific INE807F01027 Pharmaceuticals Merger ViyashLifesciences NCLTApproval